CNAT News and Press, Conatus Pharmaceuticals From 11/18/19

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member. “We are pleased to expand the perspective of our Board of Directors ...

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q3 GAAP EPS of -$0.10 beats by $0.02 . More news on: Conatus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent Developments In June 2019, Conatus announced that top-line results from its ENCORE-LF clinical...

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q2 GAAP EPS of -$0.02. More news on: Conatus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided updates on its development programs. Program Updates During the second quarter, Conatus announced ...

CNAT stock plunged more than 60% Tuesday. Why? The significant drop comes after Conatus Pharmaceuticals (NASDAQ:CNAT) said twenty-four hours prior that it will be implementing a restructuring plan due to its liver disease drug failing in a mid-stage trial. Here’s everything we kn...

Thinly traded, Conatus Pharmaceuticals (NASDAQ: CNAT ) has  appointed Oppenheimer as its financial advisor to assist in the exploration and evaluation of strategic alternatives. More news on: Conatus Pharmaceuticals Inc., Healthcare stocks news, Read more ...

SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. Ther...

SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet its primary endpoint and the company is discontinuing further treatment of patients enro...

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q1 GAAP EPS of -$0.14 misses by $0.02 . Revenue of $7M (-28.1% Y/Y) misses by $1.26M . Press Release More news on: Conatus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, ,